RE:RE:RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 BillionYesterday Nimbus Lakshimi (a subsidiary of Nimbus LLC.) was valued at $ "0" (zero) ... and today it was acquired by Japan's Takeda for US$ 4 Billion in cash + US$2 Billion in commercial milestones for a total of US$6 Billion.
https://www.businesswire.com/news/home/20221213005462/en/Takeda-to-Acquire-Nimbus-Therapeutics%E2%80%99-Highly-Selective-Allosteric-TYK2-Inhibitor-to-Address-Multiple-Immune-Mediated-Diseases